Nanotechnology RSS feeds


ENJOY THE BENEFITS

Simply Register to GAIN ACCESS to lots more info

USER LOGIN

NANOTECHNOLOGY FACTS ...

...Nanometres...
nanotechnology companies | nanotechnology info Human hair 80,000 nm wide
nanotechnology companies | nanotechnology info Red blood cell 7,000 nm wide
nanotechnology companies | nanotechnology info Water molecule 0.3 nm wide

SALES & WANTED

nanotechnology companies | nanotechnology infoNano Silver Powder
nanotechnology companies | nanotechnology infoFree Green Engine Oil

-----
What have you? - Place your ads here for FREE - *APPLY*

LATEST MEMBERS

  • PeterGay
  • George@MaRS
  • kcchee
  • neveen.samy
  • danny004
  • dragonfly

WHO'S ONLINE

There are currently 0 users and 10 guests online.

  Valid XHTML 1.0 Transitional

Button for your site

Midatech Ltd.

Address: 4 & 5 Dunmore Court
Zip: OX13 6BH

Visit this link

Phone :
+44 (0) 1235 528022

Fax :
+ 44 (0) 1235 528023

At Midatech we design and manufacture nanoparticles for therapeutics, diagnostics and coatings for devices including microchips.

Our biocompatible nanocells are manufactured through a one-step current Good Manufacturing Practise (cGMP) process in which the nanocells self-assemble.

Our nanocells have properties that make them ideal as drug delivery vehicles:

* They are water soluble and can be designed to either diffuse freely in vivo, or to target specific cells.
* A class of our nanocells have been shown to cross the Blood Brain Barrier.
* With a diameter of less than 5nm, unbound nanoparticles are freely excreted from the kidneys, reducing the likelihood of non-specific in vivo accumulation.
* Multiple ligands can be attached to a single nanoparticle, so multivalent drug delivery or receptor binding is possible, as well as heterogeneous ligand delivery.

The unique properties of Midatech's diverse nanocells create endless possibilities for healthcare and other industries.

» | Edit this entry
                                                                                                                                                                                                                                                                                          
Back to previous page Go to the top of this page